To explore the efficacy of 68Ga-GZMB PET/CT in assessing the response to neoadjuvant therapy for breast cancer, and to investigate the optimal SUVmax threshold of 68Ga-GZMB PET/CT for predicting pathological complete response (pCR), aiming to provide a new and effective means for accurately and non-invasively evaluating the efficacy of neoadjuvant therapy.
age 16-65
histologically confirmed unilateral primary invasive breast cancer
Tumor size≥2cm, axillary lymph node positive, treated with neoadjuvant therapy
complete clinical and histo-pathological information
bilateral or metastatic (stage IV) breast cancer
There has been a history of other malignancies within the past 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer
Severe systemic infection or other uncontrolled diseases
Patients with psychiatric disorders or those unable to comply with treatment due to other reasons